Advertisement
Singapore markets closed

  • Straits Times Index

    3,293.13
    +20.41 (+0.62%)
     

  • S&P 500

    5,053.70
    -16.85 (-0.33%)
     

  • Dow

    38,324.18
    -179.51 (-0.47%)
     

  • Nasdaq

    15,675.91
    -20.73 (-0.13%)
     

  • Bitcoin USD

    64,635.70
    -1,877.78 (-2.82%)
     

  • CMC Crypto 200

    1,404.59
    -19.51 (-1.37%)
     

  • FTSE 100

    8,040.38
    -4.43 (-0.06%)
     

  • Gold

    2,339.00
    -3.10 (-0.13%)
     

  • Crude Oil

    82.72
    -0.64 (-0.77%)
     

  • 10-Yr Bond

    4.6520
    +0.0540 (+1.17%)
     

  • Nikkei

    38,460.08
    +907.92 (+2.42%)
     

  • Hang Seng

    17,201.27
    +372.34 (+2.21%)
     

  • FTSE Bursa Malaysia

    1,571.48
    +9.84 (+0.63%)
     

  • Jakarta Composite Index

    7,174.53
    +63.72 (+0.90%)
     

  • PSE Index

    6,572.75
    +65.95 (+1.01%)
     

Why Iovance Stock Leaped 17% Higher Today

Eric Volkman, The Motley Fool
·2-min read
Why Iovance Stock Leaped 17% Higher Today

As revealed by Securities and Exchange Commission filings dated Thursday, everyone who is anyone at Iovance, it seems, was hitting the buy button. Wayne Rothbaum, a member of the biotech company's board of directors and the president of healthcare sector investment fund Quogue Capital, disclosed two recent purchases of 500,000 shares of Iovance's common stock. Fellow board members Michael Weiser, Ryan Maynard, and Merrill McPeak also loaded up, with recent buys totaling a respective 10,000; 7,500; and 20,000 common shares.

Continue reading